| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCNE1 |
| Uniprot No | P24864 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-410aa |
| 氨基酸序列 | MPRERRERDA KERDTMKEDG GAEFSARSRK RKANVTVFLQ DPDEEMAKID RTARDQCGSQ PWDNNAVCAD PCSLIPTPDK EDDDRVYPNS TCKPRIIAPS RGSPLPVLSW ANREEVWKIM LNKEKTYLRD QHFLEQHPLL QPKMRAILLD WLMEVCEVYK LHRETFYLAQ DFFDRYMATQ ENVVKTLLQL IGISSLFIAA KLEEIYPPKL HQFAYVTDGA CSGDEILTME LMIMKALKWR LSPLTIVSWL NVYMQVAYLN DLHEVLLPQY PQQIFIQIAE LLDLCVLDVD CLEFPYGILA ASALYHFSSS ELMQKVSGYQ WCDIENCVKW MVPFAMVIRE TGSSKLKHFR GVADEDAHNI QTHRDSLDLL DKARAKKAML SEQNRASPLP SGLLTPPQSG KKQSSGPEMA |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇涉及CCNE1重组蛋白研究的参考文献摘要概括(文献标题和作者为虚构示例，仅供参考)：
1. **文献名称**: *"Recombinant CCNE1 Expression and Interaction with CDK2 in Cell Cycle Regulation"*
**作者**: Smith A et al.
**摘要**: 该研究通过大肠杆菌表达系统制备了重组CCNE1蛋白，验证其与CDK2的体外结合活性，并证明其磷酸化功能对G1/S期转换的调控作用。
2. **文献名称**: *"Structural Analysis of CCNE1 Recombinant Protein in Cancer-associated Mutants"*
**作者**: Lee JH et al.
**摘要**: 利用重组CCNE1蛋白解析了其在卵巢癌细胞中常见突变体的三维结构，揭示了突变导致蛋白稳定性增加和泛素化降解受阻的分子机制。
3. **文献名称**: *"Development of a CCNE1 Kinase Activity Assay Using Recombinant Proteins"*
**作者**: Garcia R et al.
**摘要**: 开发了一种基于重组CCNE1/CDK2复合物的体外激酶活性检测方法，用于筛选靶向CCNE1过表达型癌症的小分子抑制剂。
4. **文献名称**: *"CCNE1 Recombinant Protein Enhances DNA Replication Stress in BRCA1-deficient Cells"*
**作者**: Chen X et al.
**摘要**: 研究发现外源性重组CCNE1蛋白在BRCA1缺失的乳腺癌细胞中加剧复制压力，提示其在合成致死治疗中的潜在应用价值。
**提示**：以上文献为示例，实际文献需通过PubMed或Web of Science等数据库搜索关键词 **"CCNE1 recombinant protein"** 或 **"Cyclin E1 purification"** 获取。
CCNE1 (Cyclin E1) is a critical regulatory protein involved in cell cycle progression, specifically governing the transition from the G1 phase to the S phase. Encoded by the *CCNE1* gene, it forms a complex with cyclin-dependent kinase 2 (CDK2), activating its kinase activity to phosphorylate key substrates like retinoblastoma protein (Rb). This phosphorylation releases transcription factors necessary for DNA replication, ensuring timely cell cycle advancement. Dysregulation of CCNE1 is strongly linked to cancer, particularly ovarian, endometrial, and breast cancers, where its overexpression drives uncontrolled proliferation, genomic instability, and therapeutic resistance. Elevated CCNE1 levels are associated with poor prognosis and chemoresistance, making it a biomarker and therapeutic target of interest.
Recombinant CCNE1 protein is engineered in vitro using expression systems (e.g., *E. coli* or mammalian cells) to produce functional, purified protein for research. It retains the ability to bind CDK2 and mimic native cyclin E1 activity, enabling studies on cell cycle mechanisms, drug screening, and antibody development. Researchers utilize it to investigate CCNE1's role in oncogenesis, validate inhibitors, or explore its interaction with tumor suppressors like p27. The recombinant form is essential for structural studies (e.g., crystallography) and functional assays (e.g., kinase activity measurements). Its availability accelerates therapeutic discovery, particularly in designing CDK2 inhibitors or targeted therapies for CCNE1-amplified cancers. However, challenges remain in translating findings to clinical applications due to CCNE1's complex regulatory networks and toxicity risks associated with cell cycle-targeted drugs.
×
